Last 7 days
-2.6%
Last 30 days
-15.8%
Last 90 days
-3.6%
Trailing 12 Months
-11.4%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
DHR | 171.1B | 30.9B | -4.16% | -10.76% | 24.67 | 5.53 | 2.20% | 7.40% |
MDT | 111.4B | 30.8B | -8.29% | -14.72% | 27.36 | 3.62 | -3.19% | -17.32% |
SYK | 110.8B | 19.0B | -5.21% | 22.61% | 46.98 | 6.01 | 8.73% | 30.37% |
ISRG | 109.4B | 6.4B | 3.09% | 43.51% | 83.37 | 17.01 | 8.89% | -20.19% |
COO | 17.6B | - | -2.11% | 9.04% | 46.93 | 5.79 | 13.20% | -60.04% |
MID-CAP | ||||||||
SWAV | 7.2T | 557.2M | 0.46% | 77.48% | 82.2K | 16.8K | 86.42% | 730.06% |
PEN | 12.0B | 884.6M | 11.70% | 122.44% | 1.8K | 13.54 | 13.08% | 200.12% |
GMED | 5.9B | 1.1B | -2.60% | -14.42% | 34.14 | 5.75 | 11.20% | 53.04% |
IRTC | 3.2B | 430.0M | -15.34% | -20.02% | -30.76 | 7.49 | 26.13% | 15.73% |
STAA | 2.8B | 294.7M | -15.81% | -11.38% | 87.64 | 9.48 | 21.32% | 9.45% |
SMALL-CAP | ||||||||
SILK | 1.2B | 150.7M | -26.10% | -4.98% | -21.96 | 7.98 | 40.31% | 1.80% |
AVNS | 1.2B | 814.3M | -15.33% | -12.83% | 25.98 | 1.42 | 6.96% | 121.89% |
BLFS | 1.0B | 163.2M | 34.38% | 72.90% | -6.86 | 6.15 | 17.84% | -885.82% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | 3.6% | 295 | 284 | 279 | 262 | 243 |
Gross Profit | 3.7% | 232 | 223 | 219 | 203 | 189 |
S&GA Expenses | 9.8% | 197 | 180 | 168 | 159 | 151 |
R&D Expenses | 6.6% | 38.00 | 36.00 | 35.00 | 34.00 | 34.00 |
EBITDA | -1.1% | 50.00 | 51.00 | 45.00 | 40.00 | - |
EBITDA Margin | -2.8% | 0.18* | 0.18* | 0.17* | 0.17* | - |
Earnings Before Taxes | -14.9% | 39.00 | 46.00 | 47.00 | 41.00 | 37.00 |
EBT Margin | -3.9% | 0.16* | 0.17* | 0.16* | 0.15* | - |
Net Income | -17.8% | 32.00 | 39.00 | 38.00 | 34.00 | 29.00 |
Net Income Margin | 0.6% | 0.14* | 0.14* | 0.13* | 0.12* | - |
Free Cahsflow | -21.6% | 18.00 | 22.00 | 24.00 | 19.00 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | 1.0% | 419 | 415 | 395 | 376 | 351 |
Current Assets | 0.4% | 313 | 312 | 297 | 296 | 274 |
Cash Equivalents | 4.0% | 90.00 | 86.00 | 129 | 202 | 193 |
Net PPE | 5.0% | 53.00 | 51.00 | 48.00 | 43.00 | 40.00 |
Goodwill | 0% | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
Liabilities | -3.3% | 80.00 | 83.00 | 75.00 | 77.00 | 75.00 |
Current Liabilities | -9.0% | 47.00 | 52.00 | 45.00 | 47.00 | 41.00 |
Shareholder's Equity | 2.0% | 339 | 332 | 320 | 299 | 276 |
Retained Earnings | 3.7% | -69.92 | -72.64 | -78.49 | -88.75 | -101 |
Additional Paid-In Capital | 1.3% | 409 | 404 | 398 | 387 | 379 |
Accumulated Depreciation | 2.6% | 37.00 | 36.00 | 35.00 | - | - |
Shares Outstanding | 0.2% | 48.00 | 48.00 | 48.00 | 48.00 | 48.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | -1.4% | 35.00 | 36.00 | 41.00 | 39.00 | 33.00 |
Share Based Compensation | 10.7% | 23.00 | 20.00 | 19.00 | 17.00 | 15.00 |
Cashflow From Investing | 8.0% | -143 | -156 | -114 | -15.77 | -14.02 |
Cashflow From Financing | -27.2% | 6.00 | 8.00 | 8.00 | 7.00 | 13.00 |
93.5%
88.8%
54.6%
Y-axis is the maximum loss one would have experienced if STAAR Surgical was unfortunately bought at previous high price.
20.6%
39.5%
13.8%
13.3%
FIve years rolling returns for STAAR Surgical.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-30 | Aspire Private Capital, LLC | unchanged | - | 23,115 | 95,925 | 0.03% |
2023-05-26 | ProShare Advisors LLC | reduced | -13.76 | 65,237 | 544,278 | -% |
2023-05-23 | ROYCE & ASSOCIATES LP | reduced | -24.45 | -13,077 | 2,765,840 | 0.03% |
2023-05-22 | PUTNAM INVESTMENTS LLC | reduced | -4.06 | 347,356 | 1,663,280 | -% |
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -0.85 | 953,905 | 4,069,900 | -% |
2023-05-22 | Raleigh Capital Management Inc. | sold off | -100 | -3,155 | - | -% |
2023-05-18 | JPMORGAN CHASE & CO | added | 14.13 | 3,703,000 | 11,055,000 | -% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | reduced | -13.07 | 407,000 | 3,209,000 | -% |
2023-05-17 | Advisory Services Network, LLC | reduced | -91.7 | -104,191 | 12,790 | -% |
2023-05-17 | VIRGINIA RETIREMENT SYSTEMS ET AL | added | 2.08 | -100,794 | 237,846 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 11.01% | 5,306,915 | SC 13G/A | |
Jan 23, 2023 | blackrock inc. | 11.9% | 5,738,044 | SC 13G/A | |
Jan 19, 2023 | baillie gifford & co | 10.87% | 5,240,456 | SC 13G/A | |
Feb 14, 2022 | palo alto investors lp | 2.40% | 1,140,511 | SC 13G/A | |
Feb 10, 2022 | vanguard group inc | 10.44% | 4,970,324 | SC 13G/A | |
Jan 27, 2022 | blackrock inc. | 11.8% | 5,622,956 | SC 13G/A | |
Jan 26, 2022 | baillie gifford & co | 11.62% | 5,529,868 | SC 13G/A | |
Jan 25, 2022 | blackrock inc. | 11.8% | 5,622,956 | SC 13G/A | |
Oct 01, 2021 | broadwood partners, l.p. | 18.1% | 0 | SC 13D/A | |
Sep 10, 2021 | vanguard group inc | 10.10% | 4,787,522 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
May 09, 2023 | 4 | Insider Trading | |
May 09, 2023 | 4 | Insider Trading | |
May 04, 2023 | 8-K | Current Report | |
May 03, 2023 | 10-Q | Quarterly Report | |
May 03, 2023 | 8-K | Current Report | |
Apr 26, 2023 | ARS | ARS | |
Apr 26, 2023 | DEF 14A | DEF 14A | |
Apr 26, 2023 | DEFA14A | DEFA14A | |
Mar 29, 2023 | 3 | Insider Trading | |
Mar 29, 2023 | 3 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-08 | Foust Warren | acquired | - | - | 20,331 | chief operating officer |
2023-05-08 | Michna Magda | acquired | - | - | 14,047 | chief clinical, regulatory, |
2023-03-20 | Francese James E | sold (taxes) | -49,469 | 62.07 | -797 | sr. vp, comm. ops., na, apac |
2023-03-20 | Gesten Samuel J | sold (taxes) | -55,366 | 62.07 | -892 | chief legal officer |
2023-03-20 | Holliday Keith | sold (taxes) | -56,297 | 62.07 | -907 | chief technology officer |
2023-03-20 | Barnes Scott D | sold (taxes) | -56,545 | 62.07 | -911 | chief medical officer |
2023-03-17 | Holliday Keith | sold | -51,001 | 61.97 | -823 | chief technology officer |
2023-03-10 | Barnes Scott D | sold (taxes) | -16,139 | 56.63 | -285 | chief medical officer |
2023-03-10 | Barnes Scott D | acquired | - | - | 10,555 | chief medical officer |
2023-03-10 | Holliday Keith | sold (taxes) | -16,082 | 56.63 | -284 | chief technology officer |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Apr. 01, 2022 | |
Income Statement [Abstract] | ||
Net sales | $ 73,528 | $ 63,200 |
Cost of sales | 15,966 | 13,936 |
Gross profit | 57,562 | 49,264 |
Selling, general and administrative expenses: | ||
General and administrative | 18,098 | 11,940 |
Selling and marketing | 26,354 | 17,270 |
Research and development | 10,310 | 7,941 |
Total selling, general and administrative expenses | 54,762 | 37,151 |
Operating income | 2,800 | 12,113 |
Other income (expense), net: | ||
Interest income (expense), net | 1,822 | (6) |
Gain (loss) on foreign currency transactions | 34 | (915) |
Royalty income | 273 | |
Other income, net | 63 | 62 |
Total other income (expense), net | 1,919 | (586) |
Income before income taxes | 4,719 | 11,527 |
Provision for income taxes | 2,009 | 1,925 |
Net income | $ 2,710 | $ 9,602 |
Net income per share: | ||
Basic | $ 0.06 | $ 0.20 |
Diluted | $ 0.05 | $ 0.19 |
Weighted average shares outstanding: | ||
Basic | 48,247 | 47,755 |
Diluted | 49,500 | 49,288 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 30, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 89,968 | $ 86,480 |
Investments available for sale | 113,879 | 125,159 |
Accounts receivable trade, net of allowance for credit losses of $43 and $20, respectively | 63,494 | 62,447 |
Inventories, net | 27,808 | 24,161 |
Prepayments, deposits and other current assets | 17,722 | 13,476 |
Total current assets | 312,871 | 311,723 |
Investments available for sale | 13,445 | 13,902 |
Property, plant and equipment, net | 53,453 | 50,921 |
Finance lease right-of-use assets, net | 303 | 342 |
Operating lease right-of-use assets, net | 31,182 | 30,270 |
Intangible assets, net | 165 | 173 |
Goodwill | 1,786 | 1,786 |
Deferred income taxes | 4,744 | 4,824 |
Other assets | 956 | 957 |
Total assets | 418,905 | 414,898 |
Current liabilities: | ||
Accounts payable | 9,102 | 11,576 |
Obligations under finance leases | 171 | 169 |
Obligations under operating leases | 3,538 | 3,524 |
Allowance for sales returns | 5,303 | 5,706 |
Other current liabilities | 28,949 | 30,741 |
Total current liabilities | 47,063 | 51,716 |
Obligations under finance leases | 167 | 210 |
Obligations under operating leases | 28,030 | 27,136 |
Deferred income taxes | 1,369 | 1,489 |
Asset retirement obligations | 218 | 220 |
Pension liability | 3,134 | 1,935 |
Total liabilities | 79,981 | 82,706 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Common stock, $0.01 par value; 60,000 shares authorized: 48,331 and 48,212 shares issued and outstanding at March 31, 2023 and December 30, 2022, respectively | 483 | 482 |
Additional paid-in capital | 409,303 | 404,189 |
Accumulated other comprehensive gain (loss) | (937) | 156 |
Accumulated deficit | (69,925) | (72,635) |
Total stockholders’ equity | 338,924 | 332,192 |
Total liabilities and stockholders’ equity | $ 418,905 | $ 414,898 |